MK-2870-010

About this trial

The purpose of this study is to compare sacituzumab tirumotecan on its own, or in combination with pembrolizumab, versus Treatment of Physician’s Choice (TPC) in patients with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. This study is looking for ways to improve treatment for breast cancer that has spread and cannot be treated with surgery (unresectable).

Patient Profile

This study is for people whose breast cancer:
1. has spread into surrounding tissues or to another part of the body.
2. has HER2-negative breast cancer, i.e.: has a small number or no receptors for HER2.
3. has HR-positive breast cancer, i.e.: a lot of hormone receptors.

Where’s this trial being run?

Bon Secours Cork, St Vincents University Hospital, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	MK-2870-010
Number:	24-113
Full Title:	An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Principal Investigator:	Prof Michaela Higgins (St Vincent's University Hospital), Prof Conleth Murphy (Bon Secours, Cork), Dr Shahid Iqbal (Mater Misericordiae University Hospital)
Type:	Industry Sponsored
Sponsor:	MSD
Recruitment Started:	Global: April 2024 Ireland: April 2024

Global Recruitment Target:	1200
Ireland Recruitment Target:	18